Aclarubicin

An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.

Also Known As:

Aclacin; Aclaplastin; MA-144A1; NSC-208734; MA 144A1; MA144A1; NSC 208734; NSC208734; Aclacinomycin A; 1-Naphthacenecarboxylic acid,(2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)oxy)-, methyl ester, (1R-(1alpha,2beta,4beta))-

Networked: 368 relevant articles (39 outcomes, 79 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wu, Depei: 8 articles (12/2020 - 05/2011)
2.	Jin, Jie: 8 articles (01/2020 - 01/2008)
3.	Zhang, Yanming: 6 articles (12/2020 - 01/2014)
4.	Liu, Limin: 6 articles (04/2019 - 01/2014)
5.	Hong, Ming: 5 articles (12/2020 - 06/2009)
6.	Huang, Jian: 5 articles (02/2016 - 01/2008)
7.	Li, Jian-Yong: 4 articles (12/2020 - 10/2007)
8.	Qian, Si-Xuan: 4 articles (12/2020 - 10/2007)
9.	Tong, Hongyan: 4 articles (01/2020 - 08/2013)
10.	Zhu, Hong-Hu: 4 articles (01/2020 - 11/2013)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/01/1995 - "Aclarubicin is therefore considered a highly active drug for remission reinduction of previously treated children suffering from ANLL with an acceptable toxicity." 12/01/1987 - "Phase II study of aclarubicin in acute myeloblastic leukemia." 06/01/1984 - "Phase I-II study of aclarubicin for treatment of acute myeloid leukemia." 04/01/1988 - "Thirty-five patients with acute myelogenous leukemia were treated with aclacinomycin A (60 mg/m2/day for 5 days) and VP-16-213 (100 mg/m2/day for 5 days). " 01/01/1987 - "Aclacinomycin-A in the induction treatment of childhood acute myelogenous leukemia."
2.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/01/1987 - "Treatment of four patients with myelodysplastic syndrome with a small dose of aclacinomycin-A." 03/01/2000 - "We have reported that low-dose aclarubicin (ACR) therapy is effective in some patients with myelodysplastic syndrome (MDS). " 12/01/1991 - "Low-dose aclarubicin has also been reported to be effective as differentiation therapy in some patients with myelodysplastic syndrome and atypical AML. " 01/01/1990 - "Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin." 09/01/1996 - "[Randomized controlled study of very low-dose Ara-C versus low-dose aclarubicin for the treatment of myelodysplastic syndrome]."
3.	Lymphatic Metastasis 12/01/1991 - "Enhanced anti-cancer effects of intralymphatic aclarubicin on distal lymph node metastases: quantitative evaluation using a new experimental model in mice." 02/01/1993 - "From these results, it appears that the new dosage form of aclacinomycin A, ACR-CH, with superior therapeutic efficacy against lymph node metastases, can also enhance the immune response of regional lymph node cells. " 09/01/1997 - "ACR-CH is designed to (a) adsorb a great amount of aclarubicin and desorb in a free state; (b) distribute a greater amount of ACR for a longer period of time selectively to the regional lymph nodes; (c) be decreased in the systemic toxicity; and (d) enhance its therapeutic effect on lymph node metastases. " 09/01/1995 - "[Trial of a treatment for lymph node metastases in patients with breast cancer using aclarubicin bound to activated carbon particles]." 09/01/1997 - "A new dosage formulation (ACR-CH), composed of aclarubicin (ACR) bound to fine activated carbon particles, has been developed for the treatment of lymph node metastases in breast cancer. "
4.	Leukemia 01/01/1987 - "[Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas]." 08/01/1986 - "Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study." 12/01/1980 - "A phase II study of aclacinomycin A in acute leukemia in adults." 09/01/1991 - "[Hypoplastic leukemia successfully treated with low-dose aclarubicin: a case report]." 01/01/1989 - "Leukemia-bearing mice receiving aclacinomycin A decreased these stem cell levels to that of drug-treated non-leukemia bearing animals.(ABSTRACT TRUNCATED AT 250 WORDS)"
5.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/01/1989 - "Twelve patients with acute lymphoblastic leukemia (ALL) were treated with aclacinomycin A (60 mg/m2/day for five days) and VP-16-213 (100 mg/m2/day). " 11/01/1989 - "Refractory acute lymphocytic leukemia: response to aclacinomycin A and VP-16-213." 01/01/1987 - "Aggressive combination chemotherapy of bone marrow relapse in childhood acute lymphoblastic leukemia containing aclacinomycin-A: a multicentric trial." 12/01/2013 - "Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients." 08/28/2015 - "Efficacy of cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen compared to FLAG regimen for adult patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia."

Related Drugs and Biologics

1.	Cytarabine (Cytosar-U)
2.	Granulocyte Colony-Stimulating Factor (G-CSF)
3.	Decitabine
4.	Homoharringtonine
5.	Dosage Forms (Dosage Form)
6.	Doxorubicin (Adriamycin)
7.	Etoposide (VP 16)
8.	Carbon
9.	Anthracyclines
10.	Daunorubicin (Cerubidine)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	CAG protocol
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Remission Induction

HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Application Error

An application error has occurred and our support engineers have been notified.

Please use the browser "Back" button and try your operation again.

OR if the error persists and you require an email response
please contact us at "cs at curehunter.com":

Your request
The circumstances of the error
Your login id/nickname or email

Return to Top Page